Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BELLUS HEALTH INC. We currently have 16 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
BELLUS HEALTH INC
BELLUS HEALTH INC
BELLUS Health – Taking Stock
15 Aug 16
It has now been nearly two months since BELLUS Health announced that its lead candidate KIACTA™ had not met its primary endpoint in the Phase 3 study completed earlier this year. The shares are 89% down since the news. The company’s recent Q3 release however tells us Shigamab™, a wholly owned programme, has shown further very strong pre-clinical data for sHUS this time in a primate model, and reminds us that BELLUS Health holds interests in a number of third party programmes that have potential we believe not currently reflected in the share price.
Where next for BELLUS Health?
21 Jun 16
The drug development company focused on rare diseases has announced top-line Phase 3 results of KIACTA™ for the treatment of AA amyloidosis. Disappointingly the study did not meet its primary efficacy endpoint (ie shown to have delayed defined adverse events at a P value of 0.05 or less) but was shown to be safe and well tolerated over treatment periods of greater than 4 years. The shares fell 79% on the day to C$0.51.
Countdown to D Day
16 May 16
The drug development company focused on rare diseases last week reported financial and operating results for the quarter ending 31 March. The numbers in themselves contained no surprises. The company made a loss of C$724k vs C$46k in Q1 2015, with the increased loss pertaining largely to a lower level of revenue recognised for accounting purposes in 2016 in relation to the VIVIMIND™ license agreement with FB Health, an increase in general and administrative costs to C$988k from $719k as well as an increase in foreign exchange loss.
Lifesciences Review - Down but not out
21 Mar 16
Stocks in the life sciences industry have struggled to regain their sparkle following the autumn 2015 sell off triggered by Hilary Clinton’s comments on drug pricing with the NASDAQ Biotechnology Index down some 22% since the beginning of the year. Indeed both sides of the presidential race have now targeted pharmaceutical companies with Donald Trump campaigning for price negotiations between drug manufacturers and Medicare
FY2015 results reveal small profit but focus now on vital Q2 KIACTATM data
04 Mar 16
Last week the drug development company focused on rare diseases reported its results for the year ended December 2015. Revenues of C$4m exceeded our C$2.5m expectation. This was due to a higher amount of revenues recognised under the service agreement with the company’s partner on KIACTATM Auven Therapeutics and VIMINDTM license agreement with FB Health. However it should be noted that the cash element of these revenues totaled C$1.3m. On that same basis the company also beat our projections in terms of profitability with a total net profit attributable to shareholders of C$202k compared to a $1.9m loss in FY2014. Year end cash and equivalents of $9.7m were in line with our expectations giving the company some headroom to advance its earlier stage programmes in the event that no deal is struck for KIACTATM this year.
Phase 3 confirmatory trial complete
22 Jan 16
BELLUS Health and its partner Auven therapeutics have announced that the KIACTATM event-driven phase 3 confirmatory study for the treatment of AA amyloidosis, has met its completion target of 120 patient events linked to the deterioration of kidney function. Top line data will take a few months to be compiled after all remaining patients have completed final study visits. The trial has spanned 50 sites worldwide. It is only once this process is complete that the data from the placebo controlled trial will be unblinded and all stakeholders (the company, its shareholders, clinicians and AA amyloidosis sufferers) will know whether the study has met with its primary endpoint which will support global regulatory approvals. The initial results are expected to be released in the second quarter of this year.
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.